Understanding how pancreatic cancer spreads through its environment
Defining pro-metastatic drivers in the pancreatic cancer tumor microenvironment
This study is looking at how changes in the TP53 gene might affect pancreatic cancer and its ability to spread, with the goal of finding new treatments that could help patients by stopping the cancer from moving to other parts of the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10980175 on NIH RePORTER |
What this research studies
This research investigates the role of the TP53 gene mutation in pancreatic cancer and how it influences the tumor microenvironment, which is crucial for the cancer's spread. The team aims to identify specific interactions between mutant p53 and other proteins that promote metastasis, particularly focusing on how these interactions affect surrounding cells. By targeting these interactions, the researchers hope to develop new therapies that can disrupt the cancer's ability to spread and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic adenocarcinoma, particularly those with mutations in the TP53 gene.
Not a fit: Patients with early-stage pancreatic cancer or those without TP53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent the spread of pancreatic cancer, potentially improving survival rates for patients.
How similar studies have performed: Previous research has shown promise in targeting genetic mutations in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Kim, Michael Paul — University of Tx Md Anderson Can Ctr
- Study coordinator: Kim, Michael Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.